Intervacc’s distribution partner Dechra launches Strangvac in Spain, Portugal, and Slovenia
Intervacc’s Strangvac Launches in Spain, Portugal, and Slovenia
Intervacc AB (publ) today announces that its European distribution partner, Dechra Pharmaceuticals PLC (“Dechra”), is launching Strangvac in Spain, Portugal, and Slovenia. Vaccine vials against the serious and contagious equine disease strangles are expected to be available for delivery in these markets shortly.
“Strangvac is approved for sale and marketing in the EU, the United Kingdom, and Norway, and has been launched in Sweden, Denmark, Finland, the United Kingdom, France, Germany, Belgium, the Netherlands, Austria, Ireland, Poland, Italy, and now also in Spain, Portugal, and Slovenia. These launches are important steps for continued market development. Strangles is a serious and contagious disease that affects the equine industry throughout Europe. By offering a vaccine developed with innovative technology and based on fused recombinant proteins, we contribute to improved animal health,” says Jonas Sohlman, CEO of Intervacc.
For more information, please contact:
Jonas Sohlman, CEO
Tel: +46 (0)8 120 10 600
Email: jonas.sohlman@intervacc.se
This information was submitted for publication on August 18, 2025, at 13:00 CET.
About Strangvac
Strangvac is a vaccine against the equine disease strangles and is approved for sale and marketing in the EU, the United Kingdom, Iceland, Norway, and Liechtenstein, and has been launched in Sweden, Denmark, Finland, the United Kingdom, France, Germany, Belgium, the Netherlands, Austria, Ireland, Poland, and Italy.
About Dechra
Dechra Pharmaceuticals is Intervacc’s exclusive distribution partner for the Strangvac vaccine in Europe, excluding the Nordic and Baltic countries. Dechra is a global specialist in veterinary pharmaceuticals and related products. Dechra has expertise in the development, manufacturing, marketing, and sales of high-quality products exclusively for veterinarians worldwide.
About Intervacc
Intervacc AB (publ) is an animal health company that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on its proprietary technology platform with fused recombinant proteins. Intervacc’s shares are listed on Nasdaq First North Growth Market.
Contact Information Certified Adviser
Eminova Fondkommission AB
Email: adviser@eminova.se, Tel: +46 (0)8 – 684 211 10
Enjoyed this post by Thibault Helle? Subscribe for more insights and updates straight from the source.
